PHARMACY

Accu-Break issues two new patents for their tablet-making technologies

BY Diana Alickaj

PLANTATION, Fla. Accu-Break Pharmaceuticals announced the recent issuance of two patents for its Accu-Break technologies on Thursday. Accu-Break is widely known for its innovation in tablet formation that includes customized and individualized dosing, for patients that need specific amounts of a drug inserted for certain medications.

The first-patent involves a tablet designed for patients with combination doses that allows them to ingest only one tablet with two different medications. The new technology enables the medications to be separated by splitting the tablet through a drug free layer. This would also be helpful in combining two different medications that are not necessarily compatible with one another, without mixing them together.

The second patent, according to published reports, will include divisible tablets which would provide an accurate partial-dose of active ingredients within the tablet, which is useful for titration and doseage adjustment.

“The Company views the issuance of these patents as key to both our own product development and the worldwide licensing of our innovative tablet technologies,” said ABP’s chief executive officer, Allan Kaplan. “The granting of these patents should bode well for additional pending applications that cover, among other things, new and complimentary tablet technologies.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

IVoice announces patent on new product for easy medicine consumption

BY Diana Alickaj

MATAWAN, N.J. iVoice has created a new product that will organize the way that patients consume pills. According to published reports, the invention is a medicine container that has speaking instructions.

iVoice has filed a patent application with the U.S. Patent and Trademark Office under the title, “Methodology for Wirelessly Loading Speaking Medicine Containers, with an internal clock.”

The new iVoice product contains an internal clock, which starts when a patient activates the audio playback that, with recurring use, creates a message that displays how many pills the patient should have left, and if that “predetermined amount” is not in the container, a warning is displayed for the patient to contact a doctor or pharmacist. Other features include a medicine container starting table count, required consumption data and self-programming.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FTC files complaint over Cephalon’s attempt at protection of Provigil market

BY Diana Alickaj

WASHINGTON Cephalon is facing a lawsuit filed by antitrust enforcers regarding its Narcolepsy medicine, Provigil.

Provigil is Cephalon’s best-selling drug, and according to the Wall Street Journal, the civil complaint filed by the Federal Trade Commission stated that Cephalon was illegally delaying the sale of the drug by four rivals that were slated to produce and market the generic version of the drug. The sales of Provigil are a recorded $800 million per year.

According to the Wall Street Journal report, companies including Teva Pharmaceuticals, Ranbaxy Pharmaceuticals, Barr Pharmaceuticals, and Mylan Pharmaceuticals, were given a combined $200 million to push off the genetic version of their drug from market entry until 2012.

Cephalon denies any wrongdoing. “The transactions we reached met the letter and spirit of the law in every way,” Frank Baldino, Cephalon’s chief executive, said, “and we will litigate this matter, and we will prevail.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?